Daily Brief Health Care: PrimeGenX Therapeutics, Manipal Health Enterprises Ltd, Guangzhou Novaken Pharm, INVO BioScience , Pure Health Holding PJSC, Jaguar Health and more

• PrimeGenX Therapeutics Co., Ltd. is a biotech company founded in 2016, specializing in locally-delivered targeted therapies for immune-inflammation diseases.
• The pipeline includes 4 proprietary drug candidates and 5 generic drug candidates, with PG-011 targeting atopic dermatitis and allergic rhinitis.
• Cash and cash equivalents were RMB127,682 thousand as of April 30, 2026, with net liabilities of RMB(7,191) thousand.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Manipal Health will launch its India IPO on July 29. The IPO consists of fresh issue of INR80B (~$829M) and OFS of up to 22M shares aggregating to INR13B.
• The IPO price band is set at INR560 to INR590 per share. The IPO subscription will close on July 31, with expected listing on August 5.
• Manipal Health proposes to utilize the net proceeds mainly for repayment/ prepayment of certain outstanding borrowings. As of May 31, 2026, the company had outstanding borrowings of INR112B.

• Founded in 2007, Guangzhou Novaken Pharm is a clinical-stage pharmaceutical company developing modified new drugs using alternative formulations and drug-delivery technologies.
• DHMP is the first dissolving microneedle drug patch approved for clinical trials in China and the only one to Phase II.
• Net current liabilities were (RMB573,269) as at May 31, 2026, with a current ratio of 0.2.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• M&A-driven top-line growth is masking severe operational cash drag and negative unit economics. While consolidated revenue grew 23% year-over-year to $2.02 million in Q1 2026, Adjusted EBITDA deteriorated to $(1.26) million, driven by rising clinic-level operating costs and heavy corporate overhead.
• The commercial thesis for INVOcell remains fundamentally flawed due to conflicting economic incentives for physicians and embryologists. High-complexity IVF laboratories depend on profitable add-ons like ICSI and PGT-A. Bypassing the lab with intravaginal culture (IVC) decimates clinic margins because there is no dedicated, highly-reimbursed CPT code for IVC.
• Recent liquidity improvements are temporary, and the newly signed $15 million Alumni Capital equity line is highly dilutive. Although warrant exercises lifted cash to $4.9 million as of March 31, 2026, the structural cash burn from operations—exceeding $5.3 million annually—means the company will heavily rely on the discount-priced stock sale program, delaying any lifting of the going concern qualification.

• Pure Health stands as the largest integrated healthcare network in the UAE, with a rapidly expanding international footprint in the US, UK, and Europe, strategically shifting its revenue base to mitigate domestic pressures.
• Financial performance shows robust top-line growth, driven by international acquisitions; however, the company faces headwinds in its domestic UAE Care segment, with declining revenues and margin compression.
• The company’s strategy is heavily focused on margin-accretive international expansion, aiming for 50% of revenue from outside the UAE, alongside leveraging technology and data to advance preventative care and the science of longevity.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Jaguar Health develops novel plant-derived prescription drugs for human GI diseases and non-prescription GI products for animals. This prospectus registers shares for resale by a selling stockholder.
• Jaguar Health received $16.0 million non-dilutive capital in January 2026 from Future Pak, with potential for $20 million in milestone payments. Crofelemer received Orphan Drug Designation for MVID.
• The company holds global unencumbered rights for crofelemer, an FDA-approved drug. Future stock resales and issuances may cause market price decline.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Critical Funding Cliff: Guangzhou Novaken Pharm is facing a severe liquidity crisis. As of May 31, 2026, the company had just 102.6 million RMB in cash against 573.3 million RMB in net current liabilities. At its current burn rate, it has a runway of roughly 8 months, making the HKEX IPO refiling on July 24, 2026 an absolute necessity for survival.
• Clinical & Operational Mismatch: While the Dexmedetomidine Hydrochloride Microneedle Patch (DHMP) has cleared Phase IIa pediatric trials as of June 2026, its real-world commercial viability is highly questionable. In busy Chinese public hospitals, where operating room turnover is strictly optimized, the patch’s 15-to-30 minute absorption timeline is a logistical dealbreaker compared to immediate intravenous (IV) injection.
• Unsolved Scale-Up and COGS Bottlenecks: Soluble microneedles cannot be manufactured using traditional high-speed transdermal machinery. Precision micro-molding, tip-loading consistency, and the lack of a standardized, non-destructive sterilization method (as aseptic manufacturing remains prohibitively expensive) keep unit costs extremely high, leaving the product highly vulnerable to pricing pressures in China’s centralized procurement system.

• Pumecitinib (PG-011) Gel’s competitive edge in China’s crowded atopic dermatitis market relies heavily on its unique gel formulation over standard creams and ointments, offering superior cosmetic elegance and rapid absorption for facial use, though it faces intense competition from established giants Hengrui and China Medical System (CMS).
• The commercialization partnerships signed with Simcere Pharmaceutical in Q2 2026 for both the gel and nasal spray formulations of Pumecitinib were a survival necessity rather than a strategic choice; PrimeGenX’s depleted cash reserves made building an in-house sales force impossible, trading long-term margin upside for near-term risk mitigation.
• With only RMB 127.68 million in cash as of April 30, 2026, and a net liability position of RMB 7.2 million, PrimeGenX is operating on a razor-thin cash runway of roughly seven months, making the success of their newly refiled HKEX IPO on July 24, 2026, a make-or-break event for the company’s survival.

• Deleveraging vs. Operational Performance: The proposed ₹5,552.76 crore debt repayment from the IPO proceeds is a balance-sheet reset that will make Manipal virtually net-debt free, but it should not be conflated with operational efficiency. Real margin expansion must come from scaling up the pro forma ARPOB of ₹66,144.59 toward peer leaders through high-acuity CONGO-R clinical integration across recently acquired networks.
• Acquisition Integration and Bed Headroom: Manipal’s rapid expansion to 13,037 licensed beds hides a massive operational delta, with only 6,878 operational beds in FY26. The primary value-creation lever is not greenfield capex, but the optimization of the 6,159 unutilized licensed beds and overcoming the post-acquisition clinical integration bottlenecks of AMRI, Medica Synergie, and Sahyadri.
• Severe Talent Cost Pressures: Doctor professional fees consume a substantial 22.72% of revenue, with aggressive competitor poaching driving specialist salary inflation of up to 12%. To protect its mid-term EBITDA margins, Manipal relies heavily on captive talent pipelines, such as its 343 DNB seats, and a transition away from minimum-guarantee doctor compensation models.

• Future Pak Deal Milestones are Not Low-Hanging Fruit: While the U.S. licensing agreement with Future Pak provided $19.0 million in upfront non-dilutive capital by Q1 2026, the remaining $20 million in milestones is tied to highly demanding cumulative commercial sales thresholds for Mytesi and full FDA approval of Canalevia-CA1 in canine chemotherapy-induced diarrhea (CID), making cash inflows from this source highly improbable in the near term.
• Crofelemer for MVID Offers Solid Clinical Signal but Negligible Market Volume: Liquid oral crofelemer demonstrated impressive efficacy in pediatric intestinal failure, showing up to a 48% reduction in parenteral support (PS) requirements at ESPGHAN 2026. However, Microvillous Inclusion Disease (MVID) is an ultra-rare congenital disorder with a global addressable patient pool of only a few hundred infants, limiting its commercial value to ultra-orphan pricing leverage rather than volume.
• Unrelenting Dilution and Debt Restructuring Signal Severe Going-Concern Risk: Despite out-licensing Mytesi’s commercial cost base to reduce SG&A, Jaguar remains structurally unprofitable with a $7.02 million net loss in Q1 2026 and $33.15 million in total debt. The newly established $40 million equity line of credit (ELOC) with C/M Capital Master Fund, LP, involving the registration of 41,000,000 shares for resale, represents massive impending dilution that will heavily depress share price post the 1-for-35 reverse stock split.